Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected)

Last updated: August 10, 2022
Sponsor: HRH Pharmaceuticals Limited
Overall Status: Completed

Phase

3

Condition

Covid-19

Treatment

N/A

Clinical Study ID

NCT04668235
FNC IGZ-1
  • Ages > 18
  • All Genders

Study Summary

Estimated number of participants: 342 participants with COVID-19 Design: Phase III, single-center, randomized, double-blind, parallel, placebo-controlled clinical study.

In December 2021, there was a drop in the number of hospitalizations and the cases of COPD, tuberculosis and HIV associated with COVID-19, which are outside the inclusion criteria of this study. After the initial data of the study, there was a discussion with Anvisa and the size of the sample calculation was revised by amendment 4 (180 participants), and the methodology of statistical analysis for a new sample calculation was "a formula for sample calculation for superiority studies using proportions, according to the book do Chow et al (Chow, S.-C., Shao, J., Wang, H., &Lokhnygina, Y. Eds. 2017. Sample Size Calculations in Clinical Research: Third Edition, Chapman and Hall/CRC). Thus, Anvisa concluded that the adjustments are in accordance with the agency's guidelines, approving E4, which was later also approved by the Ethics Committee.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Individuals aged 18 or over, regardless of gender;
  2. Patients hospitalized in moderate to severe stages in line with the Ministry of Healthclassification;
  3. Positive diagnosis for SARS-CoV-2 by molecular amplification of the virus in RT-PCRdiagnosed from a respiratory sample (nasopharynx, oropharyngeal, lower respiratorytract [eg, sputum]) collected <96 hours before randomization;
  4. Time of onset of symptoms and inclusion ≤ 14 days;
  5. Internation within 48 hours after inclusion in the study;
  6. Follow-up availability during the study period;
  7. Voluntary membership to participate in the study and signing the Informed ConsentForm.

Exclusion

Exclusion Criteria:

  1. Patients known or suspected of being sensitive to AZVUDINE or excipients (inactiveingredients: microcrystalline cellulose, hydrated lactose, polyvinylpyrrolidone K30,croscarmellose sodium, magnesium stearate);
  2. Patients diagnosed with pneumonia caused by other pathogens;
  3. Patients with liver disease (total bilirubin ≥2 times above the normal limit, ALT /TGP and AST / TGO ≥5 times above the normal limit)
  4. Patients with renal failure (glomerular filtration rate ≤60mL / min / 1.73 m2) or arereceiving continuous renal replacement therapy, hemodialysis or peritoneal dialysis;
  5. Individuals with malabsorption syndrome, or other conditions that affectgastrointestinal absorption, and circumstances in which patients need intravenousnutrition, or cannot take drugs orally or nasogastrically;
  6. Pregnant or lactating women, or women with the potential to become pregnant during thestudy period and within 6 months after the end of administration;
  7. Patients already included in other clinical trials;
  8. Patient under treatment for HIV;
  9. Patients being treated with other antivirals (eg lopinavir / ritonavir, remdesivir,umifenovir / arbidol, favipiravir, interferon-α)
  10. Patients undergoing treatment with monoclonal antibodies (eg tocilizumab and sarilumab / kevzara);
  11. Patients who are on a clinical treatment plan that includes the concomitantadministration of any other experimental treatment or off-label use of drugs alreadyon the market (eg hydroxychloroquine sulfate;
  12. Patients who require invasive mechanical ventilation or extracorporeal membraneoxygenation (ECMO) at the time of randomization;
  13. Any clinically significant medical condition or medical history that, in theinvestigator's opinion, might discourage participation in the study.

Study Design

Total Participants: 180
Study Start date:
April 23, 2021
Estimated Completion Date:
August 10, 2022

Study Description

Hypothesis:

AZVUDINE has therapeutic potential and safety profile for the treatment of patients infected with SARS-CoV-2.

Goals:

Primary objective • To assess the efficacy and safety of AZVUDINE (FNC) in relation to placebo, in patients infected with SARS-COV-2 in moderate to severe stage;

Secondary objective

• To evaluate the clinical outcome of the AZVUDINE group (FNC) compared to the placebo group in patients infected by SARS-COV-2 in moderate to severe stage;

Pharmaceutical form of the experimental medicine:

AZVUDINE 1 mg tablets

Comparators:

AZVUDINE placebo

Statistical planning:

The analyzes will be performed by FAS, PPS and SS and should be stratified by the severity of the disease (moderate, severe) and age (<60 years, ≥ 60 years), to assess the following parameters:

  • Progression of the disease (moderate to severe, severe type);

  • Negative viral load conversion rate;

  • Time of negative conversion of viral load;

  • Temperature recovery time;

  • Time necessary to improve diarrhea, myalgia, fatigue, and other symptoms;

  • Time to improve the pulmonary image;

  • Frequency of supplemental oxygenation or non-invasive ventilation;

  • Frequency of AEs;

  • Mortality rate.

All statistical tests will be bilateral tests. If the P value is ≤0.05, it is considered that there is statistical significance between the difference in the tests.

Connect with a study center

  • Santa Casa de Misericordia de Campos

    Campos Dos Goytacazes, RJ
    Brazil

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.